Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials

John R. Teerlink, Rafael Diaz, G. Michael Felker, John J.V. McMurray, Marco Metra, Scott D. Solomon, Kirkwood F. Adams, Inder Anand, Alexandra Arias-Mendoza, Tor Biering-Sørensen, Michael Böhm, Diana Bonderman, John G.F. Cleland, Ramon Corbalan, Maria G. Crespo-Leiro, Ulf Dahlström, Luis E. Echeverria Correa, James C. Fang, Gerasimos Filippatos, Cândida FonsecaEva Goncalvesova, Assen R. Goudev, Jonathan G. Howlett, David E. Lanfear, Mayanna Lund, Peter Macdonald, Vyacheslav Mareev, Shin ichi Momomura, Eileen O'Meara, Alexander Parkhomenko, Piotr Ponikowski, Felix J.A. Ramires, Pranas Serpytis, Karen Sliwa, Jindrich Spinar, Thomas M. Suter, Janos Tomcsanyi, Hans Vandekerckhove, Dragos Vinereanu, Adriaan A. Voors, Mehmet B. Yilmaz, Faiez Zannad, Lucie Sharpsten, Jason C. Legg, Siddique A. Abbasi, Claire Varin, Fady I. Malik, Christopher E. Kurtz

Research output: Contribution to journalArticlepeer-review

18 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials'. Together they form a unique fingerprint.

Medicine & Life Sciences